Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for Richter Syndrome
NCT07831395Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, pirtobrutinib, lisaftoclax and mitoxantrone hydrochloride liposome in Richter syndrome (RS), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Remission Rate at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rituximabpirtobrutiniblisaftoclaxmitoxantrone hydrochloride liposome
03
Conditions
Richter syndrome (RS)
Beyond the preview
Go deeper on NCT07831395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831395.